Reports revisited: What we learned this year

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/thomas-bethge)
(Image: iStock/thomas-bethge)

Related tags: Clinical trials, Clinical trial, Informed consent

Outsourcing models examined, market shifts scrutinized, and trial tribulations analyzed – take a look back at some of the top reports published in 2017.

Clinical trial study design: 'one size does not fit all'

The rate of false positives in clinical trials should be set higher for certain hard-to-treat cancers, suggest researchers.

Single-source outsourcing model saves pharma sponsors $45m, Tufts report

Sponsors using a single-source outsourcing partner could potentially save up to $45m through reduced time to market, according to a recent Tufts study.

Report: study design flaws slowing Parkinson's research

Researchers need to design more translationally relevant animal studies to improve the potential for success in human clinical trials, according a recent report.

Poor provider engagement drives low patient recruitment, says Tufts

Poor communication between healthcare providers and clinical research professionals is contributing to low recruitment rates, according to a recent study by Tufts.

Report: CRO turnover spikes outside the US, remains steady stateside

An increasing number of clinical trials and a decreasing amount of unemployment are creating a significant talent demand as the contract research industry continues to experience employee turnover.

'Easy to work with' tops CRO benchmarking report

With or without a preferred provider – what do pharma sponsors look for in a contract research organization?

Cost, risk, on-time and in-full: Defining value in the customer-supplier relationship

Pharmaceutical companies are more likely than their suppliers to cite cost improvement over time as the most effective metric for measuring supplier performance, according to a recent report.

GBSI report outlines steps to improve preclinical research reproducibility

The Global Biological Standards Institute (GBSI) has outlined an action plan after finding the frequency of irreproducible preclinical research exceeds 50% – costing the US nearly $28bn.

Lower participation, slower studies delaying Alzheimer's research, says IRB

At least 50,000 volunteers are needed to participate in clinical trials for Alzheimer’s disease – the global cost of which is expected to reach $2 trillion by 2030.

High-risk of issues in high-risk device trials, say researchers

Clinical trials supporting changes to high-risk medical devices often lack quality data, according to a recent report.

CMOs need to increase awareness of offerings, ISR reports

A "new set of leaders" emerged in the contract manufacturing organization (CMO) industry over the past year, though many remain unheard of, according to a recent report.

Concise without compromise: clinical trial consent forms need reader-friendly revamp

Clinical trial consent forms should be more concise moving forward, say NIH researchers in a recent report.

Of mice and human biology: when promising preclinical candidates fail in clinical trials

Researchers have developed and tested a method to determine how relevant mouse models are to human disease to better enable comparison of pharmacological targets across species.

Though willing, minorities still face barriers to clinical trial participation

Lack of trust has become less of a barrier to clinical trial participation, though more work needs to be done as information access and service levels receive low marks in a recent survey.

CRO market in Asia to see 'significant increase' through 2020

The CRO market in Asia has “massive implications” as it continues to emerge as a preferred destination for clinical trials – a global market expected to reach $57bn by 2020.

CROs, pharma to increase staff dedicated to real world data collection by 25%, Tufts report

The industry is expected to use an increasing amount of real world evidence, including social media data, which will be used to support new drug applications, according to a recent Tufts report.

Ignoring misconceptions of clinical research vs. clinical care ‘devalues participants’ dignity’

Clinical trial participants often misunderstand the differences between research and clinical care – a ‘longstanding problem’ that an enhanced informed consent process could diminish, says report.

Study database tribulations stunt trial timelines

Clinical study database challenges are delaying clinical trial timelines as CROs and sponsors must manage an increasing variety of trial data, according to a recent study.

Related news

Show more

Related products

show more

Import Risks & Clinical Supply Depots

Import Risks & Clinical Supply Depots

Catalent Pharma Solutions | 07-Nov-2018 | Case Study

A sponsor running a clinical trial in Israel arranged to ship their clinical trial product from Europe to a depot in Israel. With the protocol based in...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more